ClinicalTrials.gg
CompletedNCT02371980Updated Jan 6, 2021Results posted

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

A Phase 4 interventional study of Vortioxetine and Placebo in Major Depressive Disorder, sponsored by Takeda. Completed at 79 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
Largest of 54
1,106 · median 413
Started
2015
with 2 others
Phase 4
13 of 54
none open now
Registered
30th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one has the largest enrollment, is one of 3 that started in 2015, is one of 13 in phase 4, and was the 30th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.

Read the detailed description

The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine.

The study will enroll approximately 1100 participants. All participants will receive vortioxetine 10 mg open-label for the first 16 weeks of the study. Participants who meet the appropriate MDD response criteria from the Week 8 Visit through Week 16 Visit will be eligible for randomization into the double-blind treatment period. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Vortioxetine 5 mg
  • Vortioxetine 10 mg
  • Vortioxetine 20 mg
  • Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient

All participants will be asked to take one capsule at the same time each day throughout the study.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 weeks. Participants will make 19 visits to the clinic, and will be contacted by telephone 4 weeks after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Suffers from recurrent major depressive disorder (MDD) as the primary diagnosis according to Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition - Text Revision () criteria (classification code 296.3x), and the current episode is confirmed by the Mini International Neuropsychiatric Interview (MINI).
  4. Reported duration of the current episode is ≥8 weeks and ≤18months.
  5. Had at least 2 other major depressive episodes (MDEs) before the current episode.
  6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline I visits.
  7. Is a man or woman aged 18 to 75 years, inclusive.
  8. A female participant of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of the informed consent throughout the duration of the study and for 30 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days prior to screening or 5 half-lives prior to screening, whichever is longer.
  2. Has previously or is currently participating in this study.
  3. Has participated in 2 or more clinical studies in the year prior to screening, or has participated in a clinical trial for a psychiatric condition that is exclusionary per this protocol.
  4. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  5. Has one or more of the following:

    1. Any current psychiatric disorder which is the primary focus of treatment other than MDD as defined in the , and assessed by the MINI.
    2. Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder (OCD), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    3. Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least 3 months from the day of screening (Participant must also have negative urine drug screen at Screening and Baseline I.)
    4. Presence or history of a neurological disorder (including epilepsy) as determined by the investigator.
    5. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    6. Any Axis II disorder as defined by DSM-IV-TR that might compromise the study.
  6. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  7. Has a history of lack of response to previous adequate treatment with vortioxetine for any MDD episode with adequate treatment considered to be known dose of vortioxetine in the approved recommended dose range for at least 6 weeks duration.
  8. Has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
  9. Has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
  10. Has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
  11. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.
  12. Has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.

    Note: For the purposes of this protocol fibromyalgia, obstructive sleep apnea, chronic pain diagnosis, and morbid obesity ( of > 40) are considered unstable due to the potential impact on assessment of the primary endpoint.

  13. Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  14. Has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:

    1. A serum creatinine value >1.5 times the (ULN).
    2. A serum total value >1.5 xULN.
    3. A serum (ALT) or aspartate aminotransferase (AST) value >2 xULN.
  15. Has glycosylated () ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known stable diabetes are not excluded.
  16. Has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: Free T4 will be checked if TSH is out of range. If free T4 is abnormal the participant will be excluded.
  17. Has clinically significant abnormal vital signs as determined by the investigator.
  18. Has an abnormal (ECG) as determined by the central reader and confirmed as clinically significant by the investigator.
  19. Is positive for surface antigen (HBsAg), anti- virus (HCV) antibodies, or has a history of (HIV) infection.
  20. Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability or efficacy.
  21. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  22. Has a history of or allergies to vortioxetine.
  23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  24. The participant is considered to be treatment resistant, eg, the participant has not responded to adequate monotherapy treatments of at least 6 weeks' duration, or has only responded to combination or augmentation therapy.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,106 participants (actual)

Study arms

  • Experimental
    Open-label: Vortioxetine 10 mg

    Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.

    Drug: Vortioxetine

  • Placebo comparator
    Double-blind: Placebo

    Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.

    Drug: Placebo

  • Experimental
    Double-blind: Vortioxetine 5 mg

    Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.

    Drug: Vortioxetine

  • Experimental
    Double-blind: Vortioxetine 10 mg

    Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.

    Drug: Vortioxetine

  • Placebo comparator
    Double-blind: Vortioxetine 20 mg

    Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.

    Drug: Vortioxetine

Interventions

  • Vortioxetine capsules

    Also known as: LuAA21004

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period

    Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile.

    Time frame: From date of double-blind randomization (Week 16) up to relapse or first 28 weeks of Double-blind Period which occurs first (Up to Week 44)

Secondary outcomes

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses.

    Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  2. Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses.

    Time frame: Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

  3. Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score

    The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

    Time frame: Week 32

  4. Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period

    Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile.

    Time frame: From date of double-blind randomization (Week 16) up to relapse or 32 weeks of Double-blind Period which occurs first (Up to Week 44)

07

Results

Posted Apr 17, 2020

Participant flow

Participants took part in the study at 74 investigative sites in the United States from 10 February 2015 to 25 April 2019.

Open-label Period
Participant flow — Open-label Period
MilestoneOpen-label: Vortioxetine 10 mgDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Started11060000
Completed5800000
Not completed5260000
Withdrew: Pretreatment event/adverse event630000
Withdrew: Significant protocol deviation190000
Withdrew: Noncompliance with study drug100000
Withdrew: Lost to follow-up550000
Withdrew: Voluntary withdrawal910000
Withdrew: Pregnancy10000
Withdrew: Lack of efficacy1160000
Withdrew: Did not meet randomization criteria1620000
Withdrew: Reason not specified90000
Double-blind Period
Participant flow — Double-blind Period
MilestoneOpen-label: Vortioxetine 10 mgDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Started0151140145144
Completed070849686
Not completed081564958
Withdrew: Pretreatment event/adverse event04329
Withdrew: Significant protocol deviation02733
Withdrew: Noncompliance with study drug01223
Withdrew: Lost to follow-up08865
Withdrew: Voluntary withdrawal0128911
Withdrew: Relapse050252526
Withdrew: Reason not specified03321
Withdrew: Missing01000

Outcome measures

PrimaryTime From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period

Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored at date of withdrawal or date of Week 28 visit, whichever was earliest. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The inter-quartile range (IQR) was 25th percentile to 75th percentile.

Time frame:
From date of double-blind randomization (Week 16) up to relapse or first 28 weeks of Double-blind Period which occurs first (Up to Week 44)
Reported as:
Median · weeks
Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period
weeksDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment PeriodNA (12 to NA)NA (28 to NA)NA (28 to NA)NA (28 to NA)
Statistical analysis
  • Double-blind: Vortioxetine 5 mg · Cox Proportional Hazards Model · p = 0.006 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.517 · 95% CI 0.323 to 0.828Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.
  • Double-blind: Vortioxetine 10 mg · Cox Proportional Hazards Model · p = 0.002 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.476 · 95% CI 0.296 to 0.767Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.
  • Double-blind: Vortioxetine 20 mg · Cox Proportional Hazards Model · p = 0.003 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.483 · 95% CI 0.298 to 0.782Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher score indicates greater severity of symptoms. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. Mixed model for repeated measures (MMRM) was used for analyses.

Time frame:
Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Least squares mean · scores on scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
scores on scaleDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Change From BL II at Week 22.70 ± 0.4612.23 ± 0.4901.47 ± 0.4712.29 ± 0.481
Change From BL II at Week 44.99 ± 0.5762.56 ± 0.5991.98 ± 0.5812.48 ± 0.602
Change From BL II at Week 85.98 ± 0.6883.03 ± 0.6982.14 ± 0.6792.97 ± 0.708
Change From BL II at Week 126.43 ± 0.7043.51 ± 0.7011.92 ± 0.6842.79 ± 0.707
Change From BL II at Week 165.77 ± 0.7243.73 ± 0.7072.08 ± 0.6883.14 ± 0.712
Change From BL II at Week 205.95 ± 0.6993.34 ± 0.6731.86 ± 0.6533.18 ± 0.675
Change From BL II at Week 245.69 ± 0.7653.78 ± 0.7332.19 ± 0.7073.16 ± 0.730
Change From BL II at Week 285.07 ± 0.7743.18 ± 0.7302.72 ± 0.6993.20 ± 0.726
Change From BL II at Week 326.55 ± 0.8583.46 ± 0.8152.58 ± 0.7842.97 ± 0.815
Statistical analysis
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.421 · Least squares mean (lsm) difference: -0.48 · 95% CI -1.63 to 0.68MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.037 · Least squares mean difference: -1.23 · 95% CI -2.39 to -0.08MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.488 · Least squares mean difference: -0.41 · 95% CI -1.57 to 0.75MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.002 · Least squares mean difference: -2.43 · 95% CI -3.93 to -0.93MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -3.00 · 95% CI -4.49 to -1.51MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.001 · Least squares mean difference: -2.50 · 95% CI -4.02 to -0.98MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.001 · Least squares mean difference: -2.95 · 95% CI -4.76 to -1.13MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -3.84 · 95% CI -5.64 to -2.03MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.001 · Least squares mean difference: -3.00 · 95% CI -4.84 to -1.16MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.002 · Least squares mean difference: -2.92 · 95% CI -4.76 to -1.08MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -4.51 · 95% CI -6.34 to -2.68MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = <0.001 · Least squares mean difference: -3.64 · 95% CI -5.50 to -1.78MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.033 · Least squares mean difference: -2.04 · 95% CI -3.92 to -0.16MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -3.69 · 95% CI -5.55 to -1.82MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.007 · Least squares mean difference: -2.63 · 95% CI -4.52 to -0.73MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.004 · Least squares mean difference: -2.61 · 95% CI -4.40 to -0.82MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -4.09 · 95% CI -5.86 to -2.31MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.003 · Least squares mean difference: -2.76 · 95% CI -4.57 to -0.96MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.057 · Least squares mean difference: -1.92 · 95% CI -3.89 to 0.06MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -3.50 · 95% CI -5.46 to -1.55MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.012 · Least squares mean difference: -2.53 · 95% CI -4.51 to -0.55MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.061 · Least squares mean difference: -1.90 · 95% CI -3.88 to 0.09MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.018 · Least squares mean difference: -2.36 · 95% CI -4.31 to -0.40MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.065 · Least squares mean difference: -1.88 · 95% CI -3.87 to 0.12MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.007 · Mmrm model: -3.09 · 95% CI -5.31 to -0.86MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -3.97 · 95% CI -6.16 to -1.77MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.002 · Least squares mean difference: -3.58 · 95% CI -5.82 to -1.34MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed

The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participant who have the same diagnosis. Considering total clinical experience, a participant was assessed on severity of mental illness on the following scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill. Baseline II is defined as the last non-missing observation prior to the first dose of double-blind study drug. MMRM was used for analyses.

Time frame:
Double-blind Baseline (BL) II and Double-blind Period: Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Reported as:
Least squares mean · scores on scale
Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed
scores on scaleDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Change From BL II at Week 20.35 ± 0.0650.32 ± 0.0690.26 ± 0.0670.27 ± 0.068
Change From BL II at Week 40.61 ± 0.0750.32 ± 0.0780.30 ± 0.0760.25 ± 0.078
Change From BL II at Week 80.68 ± 0.0910.38 ± 0.0920.29 ± 0.0890.30 ± 0.093
Change From BL II at Week 120.74 ± 0.0920.46 ± 0.0910.24 ± 0.0890.35 ± 0.092
Change From BL II at Week 160.62 ± 0.0940.50 ± 0.0910.25 ± 0.0880.34 ± 0.091
Change From BL II at Week 200.61 ± 0.0940.40 ± 0.0890.17 ± 0.0860.28 ± 0.089
Change From BL II at Week 240.60 ± 0.1030.45 ± 0.0980.24 ± 0.0940.37 ± 0.097
Change From BL II at Week 280.45 ± 0.1010.33 ± 0.0940.30 ± 0.0900.34 ± 0.093
Change From BL II at Week 320.59 ± 0.1080.41 ± 0.1010.26 ± 0.0970.22 ± 0.100
Statistical analysis
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.732 · Least squares mean difference: -0.03 · 95% CI -0.20 to 0.14MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.273 · Least squares mean difference: -0.09 · 95% CI -0.26 to 0.07MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.361 · Least squares mean difference: -0.08 · 95% CI -0.24 to 0.09MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.004 · Least squares mean difference: -0.28 · 95% CI -0.48 to -0.09MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · Least Squares Mean Difference · p = 0.002 · Least squares mean difference: -0.31 · 95% CI -0.50 to -0.12MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = <0.001 · Least squares mean difference: -0.36 · 95% CI -0.55 to -0.16MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.014 · Least squares mean difference: -0.30 · 95% CI -0.54 to -0.06MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.001 · Least squares mean difference: -0.39 · 95% CI -0.63 to -0.16MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.002 · Least squares mean difference: -0.38 · 95% CI -0.62 to -0.14MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · Least Squares Mean Difference · p = 0.025 · Least squares mean difference: -0.27 · 95% CI -0.51 to -0.03MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -0.50 · 95% CI -0.74 to -0.26MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.002 · Least squares mean difference: -0.39 · 95% CI -0.63 to -0.15MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.333 · Least squares mean difference: -0.12 · 95% CI -0.36 to 0.12MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.002 · Least squares mean difference: -0.37 · 95% CI -0.61 to -0.13MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.023 · Least squares mean difference: -0.28 · 95% CI -0.53 to -0.04MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.092 · Least squares mean difference: -0.20 · 95% CI -0.44 to 0.03MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = <0.001 · Least squares mean difference: -0.44 · 95% CI -0.67 to -0.20MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.008 · Least squares mean difference: -0.33 · 95% CI -0.57 to -0.09MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.248 · Least squares mean difference: -0.16 · 95% CI -0.42 to 0.11MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.006 · Least squares mean difference: -0.37 · 95% CI -0.63 to -0.10MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.087 · Least squares mean difference: -0.23 · 95% CI -0.50 to 0.03MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.362 · Least squares mean difference: -0.12 · 95% CI -0.38 to 0.14MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.251 · Least squares mean difference: -0.15 · 95% CI -0.40 to 0.10MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.391 · Least squares mean difference: -0.11 · 95% CI -0.37 to 0.14MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · MMRM · p = 0.209 · Least squares mean difference: -0.18 · 95% CI -0.45 to 0.10MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · MMRM · p = 0.018 · Least squares mean difference: -0.33 · 95% CI -0.60 to -0.06MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · MMRM · p = 0.009 · Least squares mean difference: -0.37 · 95% CI -0.65 to -0.09MMRM with treatment, visit, BL II score, treatment by visit interaction as fixed factors, center as random effect, and unstructured covariance matrix.
SecondaryClinical Global Impression Scale-Global Improvement Scale (CGI-I) Score

The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

Time frame:
Week 32
Reported as:
Mean · scores on scale
Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score
scores on scaleDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Clinical Global Impression Scale-Global Improvement Scale (CGI-I) Score4.4 ± 1.473.9 ± 1.513.5 ± 1.723.7 ± 1.56
SecondaryTime From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period

Relapse was defined as either 1) MADRS Score ≥22, 2) lack of efficacy as determined by the investigator or 3) other unsatisfactory treatment response judged by the investigator. Time to relapse was defined as date of relapse - date of randomization + 1 (where date of relapse is the date of last dose, or date of last contact if date of last dose is missing, for participant with a relapse). Participants without relapse were censored. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score ranges from 0 to 60. Higher scores indicate greater severity of symptoms. The IQR was 25th percentile to 75th percentile.

Time frame:
From date of double-blind randomization (Week 16) up to relapse or 32 weeks of Double-blind Period which occurs first (Up to Week 44)
Reported as:
Median · weeks
Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment Period
weeksDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
Time From Randomization to Relapse of Major Depressive Disorder During the Entire 32-Week Double-Blind Treatment PeriodNA (12 to NA)NA (32 to NA)NA (32 to NA)NA (32 to NA)
Statistical analysis
  • Double-blind: Placebo vs Double-blind: Vortioxetine 5 mg · Cox Proportional Hazards Model · p = 0.002 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.481 · 95% CI 0.302 to 0.766Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 10 mg · Cox Proportional Hazards Model · p = <0.001 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.455 · 95% CI 0.286 to 0.725Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.
  • Double-blind: Placebo vs Double-blind: Vortioxetine 20 mg · Cox Proportional Hazards Model · p = 0.002 (Gate-keeping fixed-sequence testing procedure was used for multiple comparisons.) · Hazard ratio (hr): 0.484 · 95% CI 0.304 to 0.771Cox proportional hazards model with a factor for treatment and baseline II MADRS total score as a covariate, using the exact method to handle ties.

Adverse events

Collected over From first dose of study drug and up to 30 days after the last dose (Up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label: Vortioxetine 10 mg0/1,106 (0%)9/1,106 (0.8%)417/1,106 (37.7%)
Double-blind: Placebo0/151 (0%)1/151 (0.7%)16/151 (10.6%)
Double-blind: Vortioxetine 5 mg0/140 (0%)3/140 (2.1%)30/140 (21.4%)
Double-blind: Vortioxetine 10 mg1/145 (0.7%)4/145 (2.8%)27/145 (18.6%)
Double-blind: Vortioxetine 20 mg0/144 (0%)0/144 (0%)32/144 (22.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventOpen-label: Vortioxetine 10 mgDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
VertigoEar and labyrinth disorders0/11060/1511/1400/1450/144
Ankle fractureInjury, poisoning and procedural complications0/11060/1511/1400/1450/144
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/11060/1511/1400/1450/144
Post procedural cellulitisInfections and infestations0/11060/1510/1401/1450/144
PyelonephritisInfections and infestations0/11060/1510/1401/1450/144
Completed suicidePsychiatric disorders0/11060/1510/1401/1450/144
NephrolithiasisRenal and urinary disorders0/11060/1510/1401/1450/144
Cardiac failureCardiac disorders0/11061/1510/1400/1450/144
Suicidal ideationPsychiatric disorders2/11060/1510/1400/1450/144
Abdominal pain upperGastrointestinal disorders1/11060/1510/1400/1450/144
Most frequent other events
Most frequent other events
EventOpen-label: Vortioxetine 10 mgDouble-blind: PlaceboDouble-blind: Vortioxetine 5 mgDouble-blind: Vortioxetine 10 mgDouble-blind: Vortioxetine 20 mg
NauseaGastrointestinal disorders292/11062/1514/1405/14513/144
HeadacheNervous system disorders91/11060/1510/1400/1450/144
Upper respiratory tract infectionInfections and infestations0/11066/1519/1409/1459/144
Back painMusculoskeletal and connective tissue disorders0/11062/1518/1400/1452/144
NasopharyngitisInfections and infestations56/11064/1517/1407/1458/144
Weight increasedInvestigations0/11063/1515/1407/1458/144
Dry mouthGastrointestinal disorders58/11060/1510/1400/1450/144

Baseline characteristics

Safety Set for Open-label Period included all participant who received at least 1 dose of Open-label study medication. Baseline I is defined as the last non-missing observation prior to the first dose of open-label study drug.

Age, Continuous
Age, Continuous(years)Open-label: Vortioxetine 10 mg
Mean44.3 ± 13.69
Sex: Female, Male
Sex: Female, Male(Participants)Open-label: Vortioxetine 10 mg
Female807
Male299
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open-label: Vortioxetine 10 mg
Hispanic or Latino145
Not Hispanic or Latino961
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label: Vortioxetine 10 mg
American Indian or Alaska Native7
Asian19
Native Hawaiian or Other Pacific Islander10
Black or African American258
White790
More than one race19
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(Participants)Open-label: Vortioxetine 10 mg
United States1106
Height
Height(cm)Open-label: Vortioxetine 10 mg
Mean167.7 ± 9.38
Weight
Weight(kg)Open-label: Vortioxetine 10 mg
Mean82.92 ± 18.695
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Open-label: Vortioxetine 10 mg
Mean29.39 ± 5.731

2 further baseline measures are reported on the registry.

08

Study locations

79 sites
  • NoesisPharma
    Phoenix, Arizona 85032, United States
  • SW Biomedical Research, LLC
    Tucson, Arizona 85712, United States
  • CNS Research Science, Inc.
    Cerritos, California 90703, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Irvine Center for Clinical Research, Inc.
    Irvine, California 92614, United States
  • Synergy Clinical Research of Escondido
    Lemon Grove, California 91945, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pacific Institute of Medical Research
    Los Angeles, California 90024, United States
  • CNRI - Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • CNRI - San Diego, LLC
    San Diego, California 92102, United States
  • Artemis Institute for Clinical Research, LLC
    San Diego, California 92103, United States
  • University of California San Diego Medical Center
    San Diego, California 92103, United States
  • Pasadena Research Institute
    San Gabriel, California 91776, United States
  • Collaborative Neuroscience Network, LLC
    Torrance, California 90502, United States
  • Research Center for Clinical Studies, Inc.
    Norwalk, Connecticut 06851, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33067, United States
  • Gulfcoast Medical Research Center, LLC
    Fort Myers, Florida 33912, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Sarkis Clinical Trials - Parent
    Ocala, Florida 34474, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Stedman Clinical Trials, LLC
    Tampa, Florida 33613, United States
  • Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach
    West Palm Beach, Florida 33407, United States
  • Radiant Research, Inc.
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Alexian Brothers Center for Psychiatric Research
    Arlington Heights, Illinois 60005, United States
  • Rush St Lukes Presbyterian Medical Center
    Chicago, Illinois 60612, United States
  • Capstone Clinical Research, Inc.
    Libertyville, Illinois 60048, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Buynak Clinical Research
    Valparaiso, Indiana 46383, United States
  • Phoenix Medical Research, Inc.
    Prairie Village, Kansas 66208, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Lake Charles Clinical Trials, LLC
    Lake Charles, Louisiana 70629, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Potomac Grove Clinical Research Center
    Gaithersburg, Maryland 20877, United States
  • Boston Clinical Trials & Medical Research
    Boston, Massachusetts 02131, United States
  • Univ. of Massachussetts Memorial Health Care Systems
    Worcester, Massachusetts 01605-2610, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Montefiore Medical Center PRIME
    Bronx, New York 10467, United States
  • Erie County Medical Center Corporation
    Buffalo, New York 14215, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • CNS Research Science, Inc.
    Jamaica, New York 11432, United States
  • Village Clinical Research, Inc.
    New York, New York 10003, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10022, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Clinical Trials of America, Inc
    Hickory, North Carolina 28601, United States
  • NorthCoast Clinical Trials, Inc.
    Beachwood, Ohio 44122, United States
  • Patient Priority Clinical Sites, LLC
    Cincinnati, Ohio 45215, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Cutting Edge Research Group, Inc.
    Oklahoma City, Oklahoma 73116, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97214, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Keystone Clinical Studies, LLC
    Norristown, Pennsylvania 19403, United States
  • University of Pennsylvania School of Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Lincoln Research
    Lincoln, Rhode Island 02865, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29401, United States
  • Coastal Carolina Research Center, Inc
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Clinical Trials, L.P.
    Austin, Texas 78731, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Bayou City Research, Ltd.
    Houston, Texas 77007, United States
  • Houston Clinical Trials, LLC
    Houston, Texas 77098, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Radiant Research, Inc.
    Murray, Utah 84123, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298-5054, United States
  • Eastside Therapeutic Resource
    Everett, Washington 98201, United States
  • Summit Research Network (Seattle), LLC
    Seattle, Washington 98104, United States
  • Frontier Institute
    Spokane, Washington 99204, United States
  • Northbrooke Research Center
    Brown Deer, Wisconsin 53223, United States
09

References and documents

Publications

  • Thase ME, Jacobsen PL, Hanson E, Xu R, Tolkoff M, Murthy NV. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study. J Affect Disord. 2022 Apr 15;303:123-130. doi: 10.1016/j.jad.2022.02.002. Epub 2022 Feb 5. PubMed 35131363 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Mar 2019, 48 months.

Results were first posted in Apr 2020, 1 year 1 month after primary completion.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2015
First posted
Feb 26, 2015
StartActual
Feb 10, 2015
Primary completionActual
Mar 1, 2019
CompletionActual
Apr 25, 2019
Results first posted
Apr 17, 2020
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02371980
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 26, 2015
Start date
Feb 10, 2015
Primary completion
Mar 1, 2019
Completion
Apr 25, 2019
Results posted
Apr 17, 2020
Last update
Jan 6, 2021

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion